Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, branded in the U.S. as XIPERE, for the treatment of uveitic macular edema and certain other ophthalmic indications under development. Under the terms and conditions of the agreement, Arctic Vision has granted the rights of ARVN001 to Santen to commercialize the product candidate in China excluding Taiwan, Hong Kong and Macau. XIPERE for suprachoroidal use was developed by Clearside and is currently being sold in the United States by Bausch + Lomb.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Clearside Biomedical appoints Gibney as new Chair of board of directors
- Clearside Biomedical announces multiple presentations delivered at 2024 AAO
- Largest borrow rate increases among liquid names
- Clearside Biomedical management to meet with JMP Securities
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue